H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid

[1]  R. Lothe,et al.  Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes , 2005, The Journal of pathology.

[2]  G. Ehninger,et al.  Activation of the RAS Pathway Is Predictive for a Chemosensitive Phenotype of Acute Myelogenous Leukemia Blasts , 2005, Clinical Cancer Research.

[3]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[4]  Thomas J. Hudson,et al.  Cis-Acting Regulatory Variation in the Human Genome , 2004, Science.

[5]  Michael F. Olson,et al.  RAS and RHO GTPases in G1-phase cell-cycle regulation , 2004, Nature Reviews Molecular Cell Biology.

[6]  D. Spandidos,et al.  Transcriptional activation of H- and N-ras oncogenes in human cervical cancer. , 2004, Gynecologic oncology.

[7]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[8]  Yuri E Nikiforov,et al.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  S. Guil,et al.  Roles of hnRNP A1, SR Proteins, and p68 Helicase in c-H-ras Alternative Splicing Regulation , 2003, Molecular and Cellular Biology.

[10]  J. Fagin.  0888-8809/02/$15.00/0 Molecular Endocrinology 16(5):903–911 Printed in U.S.A. Copyright © 2002 by The Endocrine Society Minireview: Branded from the Start—Distinct Oncogenic Initiating Events May Determine Tumor Fate in the Thyroid , 2022 .

[11]  A. Graessmann,et al.  Modulation in vitro of H-ras oncogene expression by trans-splicing , 2001, Oncogene.

[12]  J. Fagin,et al.  The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway , 2000, Oncogene.

[13]  C. Esapa,et al.  Prevalence of Ras mutations in thyroid neoplasia , 1999, Clinical endocrinology.

[14]  M. Risio,et al.  Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation. , 1998, The American journal of pathology.

[15]  M. Pincus,et al.  Comparison of the computed three-dimensional structures of oncogenic forms (bound to GDP) of theras-Gene-Encoded p21 protein with the structure of the normal (non-transforming) wild-type protein , 1995, Journal of protein chemistry.

[16]  J. Stringer,et al.  Mitotic and post mitotic consequences of genomic instability induced by oncogenic Ha-Ras , 1995, Somatic cell and molecular genetics.

[17]  M. Risio,et al.  K-ras-2 G-C and G-T transversions correlate with DNA aneuploidy in colorectal adenomas. , 1995, Gastroenterology.

[18]  A. Giaccia,et al.  The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Adam Liwo,et al.  Comparison of the low energy conformations of an oncogenic and a non-oncogenic p21 protein, neither of which binds GTP or GDP , 1994, Journal of protein chemistry.

[20]  N. Risch,et al.  An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. , 1993, The New England journal of medicine.

[21]  A. Levinson,et al.  U1 small nuclear RNAs with altered specificity can be stably expressed in mammalian cells and promote permanent changes in pre-mRNA splicing , 1993, Molecular and cellular biology.

[22]  N. Brown,et al.  Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins. , 1991, Journal of medicinal chemistry.

[23]  N. Matheson,et al.  DNA aneuploidy in follicular thyroid neoplasia , 1991, The British journal of surgery.

[24]  G. Fleuren,et al.  Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms , 1990, International journal of cancer.

[25]  A. Levinson,et al.  Expression of the H-ras proto-oncogene is controlled by alternative splicing , 1989, Cell.

[26]  J. Hrafnkelsson,et al.  A comparative study of DNA cytometry methods for benign and malignant thyroid tissue. , 1988, American journal of clinical pathology.

[27]  M. Barbacid,et al.  ras gene Amplification and malignant transformation , 1985, Molecular and cellular biology.

[28]  Mark R. Smith,et al.  Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells , 1985, Nature.

[29]  J. Feramisco,et al.  Microinjection of the oncogene form of the human H-ras (t-24) protein results in rapid proliferation of quiescent cells , 1984, Cell.

[30]  Cori Bargmann,et al.  Mechanism of activation of a human oncogene , 1982, Nature.

[31]  R. deVere White,et al.  A stable propidium iodide staining procedure for flow cytometry. , 1982, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[32]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[33]  S. Asa,et al.  Oncogene profile of papillary thyroid carcinoma. , 1999, Surgery.

[34]  J. Rosai,et al.  Tumors of the thyroid gland , 1992 .

[35]  H. Joensuu,et al.  Comparison of nuclear DNA content in primary and metastatic differentiated thyroid carcinoma. , 1988, American journal of clinical pathology.

[36]  M. Sobrinho-Simões,et al.  The diagnostic value of flow cytometric DNA measurements in selected disorders of the human thyroid. , 1982, American journal of clinical pathology.